Health Dictionary Find a Doctor

Strongyloidiasis screening

Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Aditya Ganti M.B.B.S. [2]

Overview

Overview

Most fatal infections caused by S.stercoralis can be prevented by early detection and treatment of asymptomatic chronic infections. Screening is highly recommended to detect latent S.stercoralis infection before the start of chemotherapy or immunosuppression/steroid therapy in patients at risk. Repeated stool examination for ova and parasites or agar culture of stool may be the most appropriate approach.

Screening

Screening

Population at risk

Population at risk

  • In the U.S., residents of the Southeast may be at risk for strongyloidiasis by growing up in an endemic area.
  • Travelers and armed forces personnel may acquire infection during overseas trips to endemic areas (e.g., southeast Asia, Central and South America, and Africa).
  • Refugees and immigrants from endemic areas
  • Immunocompromised patients, especially on corticosteroid therapy, are the most vulnerable population at risk for developing disseminated disease.
  • Efforts to diagnose and screen individuals who harbor S.stercoralis should be made for patients who are candidates for immunosuppressive (e.g., corticosteroid) therapy with relevant geographic history and peripheral eosinophilia.
Screening modalities

Screening modalities

Microscopic evaluation

  • At least three ova and parasite examinations should be performed on separate days.

Serology

References

References

Looking for the patient version?

Back to the patient-friendly article

© 2026 MyEClinic – IFTM Institut für Telematik in der Medizin GmbH